4-氰基-1-甲基-4-苯基哌啶 | 3627-62-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 4-氰基-1-甲基-4-苯基哌啶
• 中文别名: 3-甲基-4-苯基-4-哌啶腈；1-甲基-4-苯基哌啶-4-甲腈
• 英文名称: 1-methyl-4-phenyl-piperidine-4-carbonitrile
• 英文别名: 1-methyl-4-cyano-4-phenylpiperidine；4-cyano-1-methyl-4-phenylpiperidine；1-Methyl-4-phenyl-4-cyan-piperidin；N-Methyl-4-phenylpiperidin-4-nitril；1-Methyl-4-phenyl-piperidin-4-carbonitril；1-N-methyl-4-cyano-4-phenylpiperidine；4-cyano-4-phenyl-N-methylpiperidine；1-Methyl-4-phenylpiperidine-4-carbonitrile
• CAS: 3627-62-1
• 化学式: C₁₃H₁₆N₂
• 分子量: 200.283
• InChiKey: ZLFQTZYFXYOGLS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  27
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-氰基-1-甲基-4-苯基哌啶 在 盐酸 、 氯化亚砜 、 水 作用下， 生成 哌替啶
  参考文献：
  名称：

  Muscarinic acetylcholine receptor binding affinities of pethidine analogs

  摘要：

  A series of pethidine analogs were synthesized and their affinities for the [H-3]N-methyl-scopolamine (NMS) binding site on muscarinic acetylcholine receptors (mAChRs) were determined using M-1, M-3 or M-5 human mAChRs expressed by Chinese hamster ovary (CHO) cell membranes. Compound 6b showed the highest binding affinities at M-1, M-3 and M-5 mAChRs (K-i = 0.67, 0.37, and 0.38 mu M, respectively). (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2015.10.029
• 作为产物：
  描述：

  1-苄基-4-氰基-4-苯基哌啶盐酸盐 在 氢气 、 palladium(II) hydroxide 、 三乙酰氧基硼氢化钠 作用下， 以 四氢呋喃 、 甲醇 、 水 为溶剂， 生成 4-氰基-1-甲基-4-苯基哌啶
  参考文献：
  名称：

  Muscarinic acetylcholine receptor binding affinities of pethidine analogs

  摘要：

  A series of pethidine analogs were synthesized and their affinities for the [H-3]N-methyl-scopolamine (NMS) binding site on muscarinic acetylcholine receptors (mAChRs) were determined using M-1, M-3 or M-5 human mAChRs expressed by Chinese hamster ovary (CHO) cell membranes. Compound 6b showed the highest binding affinities at M-1, M-3 and M-5 mAChRs (K-i = 0.67, 0.37, and 0.38 mu M, respectively). (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2015.10.029

文献信息

• [EN] NAPHTHYL ETHER COMPOUNDS AND THEIR USE<br/>[FR] COMPOSES DE NAPHTYL ETHER ET LEUR UTILISATION
  申请人：ASTRAZENECA AB

  公开号：WO2004022539A1

  公开（公告）日：2004-03-18

  Compounds having the following structure wherein R1, R2, R3, R4, R5, R6, R7 m and n are as defined in the specification, in vivo-hydrolysable precursors thereof, pharmaceutically-acceptable salts thereof, the use in therapy and pharmaceutical compositions and methods of treatment using the same.

  具有以下结构的化合物，其中R1、R2、R3、R4、R5、R6、R7、m和n如规范中定义，其体内可水解的前体，其药用盐，以及在治疗中的使用、制药组合物和使用相同的治疗方法。
• Benzamides
  申请人：H. Lundbeck A/S

  公开号：US20140107340A1

  公开（公告）日：2014-04-17

  The present invention is directed to benzamide containing compounds which inhibit the P2X7 receptor

  本发明涉及含有抑制P2X7受体的苯甲酰胺类化合物。
• [EN] ANTIDIABETIC SUBSTITUTED HETEROARYL COMPOUNDS<br/>[FR] COMPOSÉS HÉTÉROARYLES SUBSTITUÉS ANTIDIABÉTIQUES
  申请人：MERCK SHARP & DOHME

  公开号：WO2015089809A1

  公开（公告）日：2015-06-25

  The present invention relates to a compound represented by formula I: and pharmaceutically acceptable salts thereof. The compounds of formula I are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.

  本发明涉及一种由公式I表示的化合物：以及它们的药用可接受盐。公式I的化合物是G蛋白偶联受体40（GPR40）的激动剂，可用于治疗、预防和抑制由G蛋白偶联受体40介导的疾病。本发明的化合物可用于治疗2型糖尿病，以及通常与该疾病相关的状况，包括肥胖和脂质紊乱，如混合型或糖尿病性血脂异常、高脂血症、高胆固醇血症和高甘油三酯血症。
• [EN] ANTIDIABETIC SUBSTITUTED HETEROARYL COMPOUNDS<br/>[FR] COMPOSÉS D'HÉTÉROARYLE SUBSTITUÉ ANTIDIABÉTIQUES
  申请人：MERCK SHARP & DOHME

  公开号：WO2015095256A1

  公开（公告）日：2015-06-25

  The present invention relates to a compound represented by formula (I): and pharmaceutically acceptable salts thereof. The compounds of formula I are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.

  本发明涉及一种由公式（I）表示的化合物：以及药学上可接受的盐。公式I的化合物是G蛋白偶联受体40（GPR40）的激动剂，并且可能对由G蛋白偶联受体40介导的疾病的治疗、预防和抑制有用。本发明的化合物可能在治疗2型糖尿病，以及通常与该疾病相关的状况，包括肥胖和脂质紊乱，如混合型或糖尿病性血脂异常、高脂血症、高胆固醇血症和高甘油三酯血症中有用。
• [EN] NAPHTHAMIDE DERIVATIVES AND THEIR USE<br/>[FR] DERIVES DE NAPHTAMIDE ET LEUR UTILISATION
  申请人：ASTRAZENECA AB

  公开号：WO2004020411A1

  公开（公告）日：2004-03-11

  Compounds having the following structure wherein R1, R2, R3, R4, m and n are as defined in the specification, in vivo-hydrolysable precursors thereof, pharmaceutically-acceptable salts thereof, the use in therapy and pharmaceutical compositions and methods of treatment using the same.

  具有以下结构的化合物，其中R1、R2、R3、R4、m和n如规范中定义，其体内可水解的前体，其药用可接受的盐，以及在治疗中的使用、制药组合物和使用相同方法的治疗方法。